Literature DB >> 21335444

NCCN Task Force report: optimizing treatment of advanced renal cell carcinoma with molecular targeted therapy.

Gary R Hudes, Michael A Carducci, Toni K Choueiri, Peg Esper, Eric Jonasch, Rashmi Kumar, Kim A Margolin, M Dror Michaelson, Robert J Motzer, Roberto Pili, Susan Roethke, Sandy Srinivas.   

Abstract

The outcome of patients with metastatic renal cell carcinoma has been substantially improved with administration of the currently available molecularly targeted therapies. However, proper selection of therapy and management of toxicities remain challenging. NCCN convened a multidisciplinary task force panel to address the clinical issues associated with these therapies in attempt to help practicing oncologists optimize patient outcomes. This report summarizes the background data presented at the task force meeting and the ensuing discussion.

Entities:  

Mesh：

Year:  2011        PMID： 21335444      PMCID： PMC4659363          DOI： 10.6004/jnccn.2011.0124

Source DB:  PubMed          Journal:  J Natl Compr Canc Netw        ISSN： 1540-1405            Impact factor:   11.908


  115 in total

1.  Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer.

Authors:  R C Flanigan; S E Salmon; B A Blumenstein; S I Bearman; V Roy; P C McGrath; J R Caton; N Munshi; E D Crawford
Journal:  N Engl J Med       Date:  2001-12-06       Impact factor: 91.245

Review 2.  Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis.

Authors:  Xiaolei Zhu; Shenhong Wu; William L Dahut; Chirag R Parikh
Journal:  Am J Kidney Dis       Date:  2007-02       Impact factor: 8.860

3.  Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer.

Authors:  Michael Atkins; Meredith Regan; David McDermott; James Mier; Eric Stanbridge; Amanda Youmans; Philip Febbo; Melissa Upton; Mirna Lechpammer; Sabina Signoretti
Journal:  Clin Cancer Res       Date:  2005-05-15       Impact factor: 12.531

4.  Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors.

Authors:  Oriol Casanovas; Daniel J Hicklin; Gabriele Bergers; Douglas Hanahan
Journal:  Cancer Cell       Date:  2005-10       Impact factor: 31.743

Review 5.  Update on novel agents in renal cell carcinoma.

Authors:  Ila Tamaskar; Roberto Pili
Journal:  Expert Rev Anticancer Ther       Date:  2009-12       Impact factor: 4.512

6.  Sequential use of the tyrosine kinase inhibitors sorafenib and sunitinib in metastatic renal cell carcinoma: a retrospective outcome analysis.

Authors:  Christian Eichelberg; Roman Heuer; Felix K Chun; Kristin Hinrichs; Mario Zacharias; Hartwig Huland; Hans Heinzer
Journal:  Eur Urol       Date:  2008-08-08       Impact factor: 20.096

7.  High-resolution analysis of DNA copy number alterations and gene expression in renal clear cell carcinoma.

Authors:  T Yoshimoto; K Matsuura; S Karnan; H Tagawa; C Nakada; M Tanigawa; Y Tsukamoto; T Uchida; K Kashima; S Akizuki; I Takeuchi; F Sato; H Mimata; M Seto; M Moriyama
Journal:  J Pathol       Date:  2007-12       Impact factor: 7.996

8.  Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2.

Authors:  S A Rosenberg; J C Yang; S L Topalian; D J Schwartzentruber; J S Weber; D R Parkinson; C A Seipp; J H Einhorn; D E White
Journal:  JAMA       Date:  1994 Mar 23-30       Impact factor: 56.272

9.  Cytogenetic profile predicts prognosis of patients with clear cell renal cell carcinoma.

Authors:  Tobias Klatte; P Nagesh Rao; Michela de Martino; Jeffrey LaRochelle; Brian Shuch; Nazy Zomorodian; Jonathan Said; Fairooz F Kabbinavar; Arie S Belldegrun; Allan J Pantuck
Journal:  J Clin Oncol       Date:  2009-01-05       Impact factor: 44.544

10.  Loss of chromosome 9p is an independent prognostic factor in patients with clear cell renal cell carcinoma.

Authors:  Matteo Brunelli; Albino Eccher; Stefano Gobbo; Vincenzo Ficarra; Giacomo Novara; Paolo Cossu-Rocca; Franco Bonetti; Fabio Menestrina; Liang Cheng; John N Eble; Guido Martignoni
Journal:  Mod Pathol       Date:  2007-09-28       Impact factor: 7.842
View more
  13 in total

1.  NCCN Working Group report: designing clinical trials in the era of multiple biomarkers and targeted therapies.

Authors:  Alan P Venook; Maria E Arcila; Al B Benson; Donald A Berry; David Ross Camidge; Robert W Carlson; Toni K Choueiri; Valerie Guild; Gregory P Kalemkerian; Razelle Kurzrock; Christine M Lovly; Amy E McKee; Robert J Morgan; Anthony J Olszanski; Mary W Redman; Vered Stearns; Joan McClure; Marian L Birkeland
Journal:  J Natl Compr Canc Netw       Date:  2014-11       Impact factor: 11.908

Review 2.  Histone deacetylases in kidney development: implications for disease and therapy.

Authors:  Shaowei Chen; Samir S El-Dahr
Journal:  Pediatr Nephrol       Date:  2012-06-22       Impact factor: 3.714

3.  Establishment and characterization of a lung cancer cell line, SMC-L001, from a lung adenocarcinoma.

Authors:  So-Jung Choi; Hyeseon Lee; Chungyoul Choe; Yong-Sung Shin; Jinseon Lee; Sung-Hwan Moon; Jhingook Kim
Journal:  In Vitro Cell Dev Biol Anim       Date:  2014-02-26       Impact factor: 2.416

4.  Modulation of Angiogenesis, Proliferative Response and Apoptosis by β-Sitosterol in Rat Model of Renal Carcinogenesis.

Authors:  Ramalingam Sharmila; Ganapathy Sindhu
Journal:  Indian J Clin Biochem       Date:  2016-05-24

Review 5.  Current Status and Future Directions of Immunotherapy in Renal Cell Carcinoma.

Authors:  Bryden Considine; Michael E Hurwitz
Journal:  Curr Oncol Rep       Date:  2019-03-08       Impact factor: 5.075

6.  The Impact of Tonsillectomy upon the Risk of Oropharyngeal Carcinoma Diagnosis and Prognosis in the Danish Cancer Registry.

Authors:  Carole Fakhry; Klaus K Andersen; Jane Christensen; Nishant Agrawal; David W Eisele
Journal:  Cancer Prev Res (Phila)       Date:  2015-04-20

Review 7.  Current treatment considerations in metastatic renal cell carcinoma.

Authors:  Housam Haddad; Brian I Rini
Journal:  Curr Treat Options Oncol       Date:  2012-06

Review 8.  PD-1 blockade in renal cell carcinoma: to equilibrium and beyond.

Authors:  Lauren C Harshman; Charles G Drake; Toni K Choueiri
Journal:  Cancer Immunol Res       Date:  2014-12       Impact factor: 11.151

9.  Unilateral renal artery stenosis with renal atrophy in a patient with metastatic papillary thyroid carcinoma treated with sorafenib.

Authors:  Hassan Shawa; Naifa L Busaidy; Dawid Schellingerhout; Mouhammed Amir Habra
Journal:  BMJ Case Rep       Date:  2013-05-15

Review 10.  Expert Recommendations for First-Line Management of Metastatic Renal Cell Carcinoma in Special Subpopulations.

Authors:  Javier Puente; Xavier García Del Muro; Álvaro Pinto; Nuria Láinez; Emilio Esteban; José Ángel Arranz; Enrique Gallardo; María José Méndez; Pablo Maroto; Enrique Grande; Cristina Suárez
Journal:  Target Oncol       Date:  2016-04       Impact factor: 4.493
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.